View looking up to central atrium Skylight
Dr James Cronin

Dr James Cronin

Associate Professor, Biomedical Sciences

Telephone number

+44 (0) 1792 606409

Email address

Welsh language proficiency

Basic Welsh Speaker

Research Links

Academic Office - 205
Second Floor
Institute of Life Science 1
Singleton Campus
Available For Postgraduate Supervision


James obtained a BSc in Medical Microbiology from King’s College London, an MSc from School of Medicine, Cardiff University and was awarded a PhD from Swansea University Medical School for investigating the role inflammation plays in throat cancer progression. James has keen interests in the roles metabolism and the immune system play in disease progression. In particular, James’ group focuses on the aberrant cell signalling pathways that lead to chronic inflammatory diseases and resistance to chemotherapy in cancer.

Areas Of Expertise

  • Cancer
  • Metabolism
  • Innate Immunity
  • Inflammation
  • Chronic disease
  • Cell Signalling
  • Immunology

Career Highlights

Teaching Interests

James lectures on the Genetics and Biochemistry Degree programmes and is a Fellow of The Higher Education Academy. James’ teaching focuses on Human Immunology, Medical Genetics (Module coordinator), Biomedical techniques (Module coordinator) and Cancer Immunotherapy at BSc and Masters levels.


The metabolic landscape of tumours is complex. Metabolic flexibility enables tumour cells to generate adenosine triphosphate (ATP), the cell’s main energy-providing molecule, whilst also committing resources to the cellular pathways that provide the building-blocks essential for cancer cell survival, growth and proliferation. Importantly, a growing body of evidence indicates that metabolic cooperation in the tumour microenvironment, between cancer cells with different but complimentary metabolic profiles, can drive cancer progression. James’ research focuses on the concept of metabolic flexibility in cancer cells and how this phenomenon contributes to cancer cell proliferation, invasion, migration and resistance to chemotherapy. Identifying the metabolic pathways that cancer cells use to adapt to restricted nutrients and oxygen may identify new therapeutic targets in cancer. James’ group use 2D and 3D cancer models to explore how cancer cells adapt to restricted nutrients and oxygen (hypoxia) in the tumour-microenvironment.  We identify key metabolic pathways using Stable isotope tracer analysis (SITA) by GC-MS, short-interfering RNA, and the Seahorse XF Bioanalyzer, amongst other metabolic assays.


James has extensive collaborations in the UK, Europe and Brazil.